What is Alimetry?
Alimetry is a specialized medical technology firm at the forefront of gastric diagnostics. Its flagship innovation, the Gastric Alimetry system, utilizes advanced Body Surface Gastric Mapping to provide clinicians with precise, data-driven insights into gastric function, motility, and electrophysiology. By addressing the diagnostic gap for patients with chronic gastric symptoms, Alimetry enables healthcare providers to establish clearer treatment pathways and more effective management strategies for complex gastrointestinal conditions. The company operates at the intersection of clinical research and patient-centric care, serving as a critical partner for healthcare facilities seeking to modernize their diagnostic infrastructure.
How much funding has Alimetry raised?
Alimetry has raised a total of $18M across 1 funding round:
Series A
$18M
Series A (2024): $18M with participation from American Gastroenterological Association, GD1 (Global From Day One), and Icehouse Ventures
Key Investors in Alimetry
American Gastroenterological Association
A professional association dedicated to advancing digestive health through clinical research, educational resources, and strategic funding for innovative medical solutions.
GD1 (Global From Day One)
A venture capital firm focused on scaling high-growth New Zealand technology companies into global market leaders through strategic advisory and capital support.
Icehouse Ventures
An active early-stage venture firm with significant assets under management, specializing in backing ambitious founders and fostering world-class innovation within the New Zealand ecosystem.
What's next for Alimetry?
Looking ahead, Alimetry is poised to leverage its recent capital influx to broaden the clinical adoption of its Gastric Alimetry system. The strategic focus will likely center on expanding its regulatory approvals and commercial presence in key global markets, particularly within the United States. By continuing to integrate advanced electrophysiological data into routine clinical workflows, the company aims to establish its diagnostic platform as the gold standard for gastric motility assessment. Future growth will be driven by ongoing research initiatives and the scaling of its commercial team to meet the rising demand for non-invasive, high-fidelity diagnostic tools in gastroenterology.
See full Alimetry company page
